You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Colorcon
Johnson and Johnson
Moodys
AstraZeneca

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LY2606368


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LY2606368?

LY2606368 is an investigational drug.

There have been 16 clinical trials for LY2606368. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Neoplasms, Preleukemia, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Children's Oncology Group.

There are three US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for LY2606368
TitleSponsorPhase
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialEli Lilly and CompanyPhase 1

See all LY2606368 clinical trials

Clinical Trial Summary for LY2606368

Top disease conditions for LY2606368
Top clinical trial sponsors for LY2606368

See all LY2606368 clinical trials

US Patents for LY2606368

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2606368   Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2606368   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
LY2606368   Start Trial 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.